611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
Shorter COVID Quarantine for College Athletes a Good Idea, Study FindsWhat Happened to the Flu This Year?3 Steps Could Nearly Eliminate COVID Infections on College Campuses: StudyPharmacy Chains Ready to Supply COVID-19 Vaccines to AmericansI've Already Had COVID-19, Do I Need the Vaccine?What Will COVID-19 Look Like Years From Now?First Computer Model of Entire COVID Virus Will Aid ResearchStopping Common Heart Meds Could Be Risky for Kidney PatientsU.S. COVID Vaccine Rollout Nears 1 Million Doses Per DayJohnson & Johnson's One-Dose COVID Vaccine Promising in Early TrialLockdowns' Benefits for Air Quality Weren't as Big as Thought: StudyPeople's 'Microbiomes' Might Influence COVID-19 Severity: StudyNew Insights Into How COVID-19 Damages the BrainCollege Campuses Are COVID 'Superspreaders,' Study FindsStuck at Home, Suffering With COVID? Experts Offer Guidance on CareCOVID Daily Death Toll Sets New U.S. Record, Soars Past 4,400AHA News: Registries Could Offer Insight Into COVID-19's Impact on College Athletes' HeartsResearch Reveals Why COVID Pneumonia Is More DeadlyPandemic Is Tied to Big Rise in U.S. Heart DeathsCommon Diabetes Meds Tied to Serious COVID-19 ComplicationPlant-Based Diet Brings Better 'Microbiome,' Healthier LifeAnswering Your Qs on the New COVID VaccinesEven Mild Cases of COVID Can Leave 'Long-Haul' Illness, Study ShowsCommon Blood Pressure Meds Won't Up Risks for COVID Patients: StudySix Months Later, Most Wuhan COVID Survivors Still Have Health IssuesHealth Officials Work to Speed Up U.S. COVID Vaccine RolloutAllergists' Group Offers Guidelines on COVID-19 VaccinesFacebook Posts Big Drivers in Vaccine Resistance, Study FindsBlack Patients at Higher Risk When Type 1 Diabetes and COVID CombineBiden Says He Will Release All Vaccine Doses After Taking Office'Pandemic Fatigue' Setting in? Here's How to Stay Safe and StrongCould High Pollen Levels Trigger Pelvic Pain?Record Number of COVID Cases, Deaths Reported in U.S.COVID Survivors' Plasma Might Prevent Worsening Illness in Older Patients: StudyAHA News: Dr. Dre Recovering From a Brain Aneurysm. What Is That?Certain Antibiotics Linked With Upped Risk for Deadly Aortic AneurysmsDeath Risk Nearly Doubles When COVID Strikes People With Heart FailureMore Infectious COVID Variant Likely Widespread in the U.S., Experts SayRed Cross Issues Call for More Blood Plasma to Treat COVID PatientsPediatricians' Group Says School Is Priority, With Proper Safety MeasuresMoves, Evictions Often Trigger Harmful Breaks in Health Care: StudyAllergic Reactions to COVID Vaccines Are Rare, Resolved on Site: CDCSurvey Shows Mental Woes Spiked in U.S. Pandemic's First MonthsYour 'To-Do' List as You Await a COVID VaccineSome Americans Can't Access Telemedicine, Study ShowsU.S. COVID Hospitalizations Reach Record High as California Hospitals Run Out of OxygenVaccine Rollout Could Have Americans Back to Normalcy by Summer, Expert SaysCould Umbilical Cord Stem Cells Be a Lifesaver Against Severe COVID-19?Kids With Congenital Heart Disease Face Higher Odds of Mental Health IssuesAlmost 47 Million Americans Already Infected With Coronavirus by Nov. 15: Study
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Another Study Casts Doubt on 'Convalescent Plasma' as COVID-19 Treatment

HealthDay News
by By Ernie Mundell HealthDay Reporter
Updated: Nov 25th 2020

new article illustration

WEDNESDAY, Nov. 25, 2020 (HealthDay News) -- Early in the COVID-19 pandemic, anecdotal reports suggested that infusing very sick patients with the blood plasma of people who'd survived the disease might help boost outcomes.

But study findings released Nov. 24 in the New England Journal of Medicine, along with disappointing results from prior trials, suggest that those initial hopes may have been unfounded.

The new study was conducted by researchers in Argentina. It compared outcomes for 228 hospitalized COVID-19 patients who got an infusion of so-called "convalescent plasma" against those of 105 patients who did not (the "placebo group"). All were so sick as to have developed pneumonia.

However, one month later, "no significant difference was noted between the convalescent plasma group and the placebo group" in terms of clinical outcomes, with about 11% of patients dying in both groups, according to a team led by Dr. V.A. Simonovich of the Italian Hospital of Buenos Aires.

The theory behind the use of survivors' blood plasma in people battling COVID-19 is that plasma contains immune system agents that might aid recipients in their fight against the disease.

But a prior study from India — this time in patients with "moderate" COVID-19 — also found little benefit of the treatment in stopping illness from progressing to a more severe stage. That study was led by Dr. Anup Agarwal, of the Indian Council of Medical Research in New Delhi, and was published Oct. 22 in the BMJ.

According to one U.S. expert unconnected to either trial, it may be time to give up on convalescent plasma as a viable COVID-19 treatment.

"There have been several major trials that have shown the same results: Convalescent plasma does not seem to have an impact on the course of COVID-19," said Dr. Mangala Narasimhan. She's senior vice president and director of Critical Care Services at Northwell Health, in New Hyde Park, N.Y.

Narasimhan also noted that in the Argentinian trial, "even with good measurement of the amount of antibody they were giving people [in the transfusions], there was no benefit seen."

She believes that other treatments should remain first-line options for severe COVID-19.

"The new monoclonal antibodies will give a more targeted and reliable antibody load to COVID-19 patients and may have an impact on the course of disease if given early after positive testing," Narasimhan said.

More information

Find out more about how to treat coronavirus at home from the U.S. Centers for Disease Control and Prevention.

SOURCES: New England Journal of Medicine, Nov. 24, 2020; Mangala Narasimhan, DO, SVP, director of critical care services, Northwell Health, New Hyde Park, N.Y.